medi glp 1 California's Proposal to Cut GLP-1 Coverage for Medi-Cal POS Glucagon-Like Peptide 1 Receptor Form:Capsule

medi glp 1 California's Proposal to Cut GLP-1 Coverage for Medi-Cal POS Glucagon-Like Peptide 1 Receptor Form:Capsule

Glucagon-Like Peptide 1 Receptor Agonists and the Eye

Who Should Choose Tirzepatide: Ideal Candidates: Need maximum weight loss (50+ pounds) Want most effective medication available Can afford $349-$1,069/month depending on option Have BMI ≥30 (or ≥27 with comorbidities) Plateaued on semaglutide or other medications No contraindications to GLP-1/GIP agonists Particularly Good For: Significant obesity (BMI ≥35) Previous weight loss medication failures Those who want best possible results Patients who tolerate GLP-1s well Cost Comparison: Value Analysis: Cost per % Body Weight Lost: Brand-Name Tirzepatide: 22.5% loss at $12,828/year Cost per %: $570 Compounded Tirzepatide (TrimRx): 22.5% loss at $4,188/year Cost per %: $186 Compounded Semaglutide (TrimRx): 14.9% loss at $2,388/year Cost per %: $160 Both compounded options offer excellent value, with semaglutide being slightly more cost-efficient per percentage lost, while tirzepatide produces greater absolute weight loss

POS

Form:Capsule

GLP-1 receptor agonists—including semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)—are used to manage type 2 diabetes and obesity in the UK